Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$1.45 +3.6%	$1.32	$1.05 ▼ $8.79	$94.61M	-0.11	204,297 shs	145,674 shs
COYA Coya Therapeutics	$6.09 +2.4%	$5.86	$4.65 ▼ $10.24	$99.51M	0.26	83,647 shs	39,841 shs
NRSN NeuroSense Therapeutics	$1.08 -40.0%	$1.97	$0.60 ▼ $2.60	$24.60M	1.66	236,302 shs	1.58 million shs
ZURA Zura Bio	$1.50 +7.1%	$1.28	$0.97 ▼ $5.07	$95.72M	-0.06	966,579 shs	471,118 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	+3.57%	0.00%	+15.08%	+14.17%	+144,999,900.00%
COYA Coya Therapeutics	+2.35%	-8.70%	+5.36%	-4.40%	-11.22%
NRSN NeuroSense Therapeutics	-40.00%	-46.80%	-43.16%	+4.85%	+42.14%
ZURA Zura Bio	+7.14%	-8.54%	+33.93%	+2.04%	-62.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLYM Climb Bio	2.3423 of 5 stars	3.6	0.0	0.0	2.5	1.3
COYA Coya Therapeutics	1.957 of 5 stars	3.5	3.0	1.9	0.8	0.0
NRSN NeuroSense Therapeutics	2.0731 of 5 stars	3.5	4.0	0.6	1.7	0.0
ZURA Zura Bio	3.6303 of 5 stars	3.6	5.0	3.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.25	Buy	$9.00	520.69% Upside
COYA Coya Therapeutics	3.00	Buy	$16.50	170.94% Upside
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	1,196.30% Upside
ZURA Zura Bio	3.13	Buy	$14.33	855.56% Upside

Current Analyst Ratings Breakdown

Latest NRSN, ZURA, COYA, and CLYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/10/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$7.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/12/2025	NRSN NeuroSense Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A
COYA Coya Therapeutics	$3.69M	27.64	N/A	N/A	$2.37 per share	2.57
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	$0.19 per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$73.90M	-$2.38	N/A	N/A	N/A	N/A	-43.95%	-42.94%	8/13/2025 (Estimated)
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	8/11/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	N/A
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-42.84%	-35.22%	8/12/2025 (Estimated)

Latest NRSN, ZURA, COYA, and CLYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	CLYM Climb Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ZURA Zura Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	14.25	14.25
COYA Coya Therapeutics	N/A	8.84	8.84
NRSN NeuroSense Therapeutics	N/A	2.21	2.21
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
COYA Coya Therapeutics	39.75%
NRSN NeuroSense Therapeutics	1.04%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	0.80%
COYA Coya Therapeutics	12.00%
NRSN NeuroSense Therapeutics	27.40%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	67.58 million	67.04 million	N/A
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable
ZURA Zura Bio	3	68.38 million	58.65 million	Optionable

NRSN, ZURA, COYA, and CLYM Headlines

Recent News About These Companies

Robert Lisicki on Living Up to Zura Bio’s Heroic Namesake

July 31 at 2:47 AM | pharmexec.comP

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18, 2025 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by Analysts

July 13, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Trading 12.5% Higher - Here's What Happened

July 10, 2025 | marketbeat.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.comS

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 25, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, ZURA, COYA, and CLYM Company Descriptions

Climb Bio NASDAQ:CLYM

$1.45 +0.05 (+3.57%)

As of 08/1/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Coya Therapeutics NASDAQ:COYA

$6.09 +0.14 (+2.35%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.06 -0.04 (-0.57%)

As of 08/1/2025 04:10 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

NeuroSense Therapeutics NASDAQ:NRSN

$1.08 -0.72 (-40.00%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.13 +0.05 (+4.63%)

As of 08/1/2025 07:52 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Zura Bio NASDAQ:ZURA

$1.50 +0.10 (+7.14%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.50 0.00 (0.00%)

As of 08/1/2025 07:51 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time